IL-23p19 Antagonists vs. Ustekinumab for Treatment of Crohn’s Disease: A Meta-analysis of Randomized Controlled Trials

By sjmartinez • March 13, 2025

Dziegielewski C, Yuan Y, Ma C, Boland BS, Chang JT, Syal G, Vuyyuru SK, Peyrin-Biroulet L, Jairath V, Singh S. IL-23p19 Antagonists vs. Ustekinumab for Treatment of Crohn's Disease: A Meta-analysis of Randomized Controlled Trials. Am J Gastroenterol. 2025 Mar 12. doi: 10.14309/ajg.0000000000003406. Epub ahead of print. PMID: 40071763.

Tags: Digestive Diseases, Publications

MicroRNA Sequencing of Serum Exosomes Reveals miR205-5p as an Anti-Fibrogenic Factor Against Intestinal Fibrosis in Crohn’s Disease

Xie Y, van Daelen M, Park R, Almaraz I, Fontenot L, Rieder F, Ho W, Limketkai B, Shih DQ, Wei M, Li Y, Koon HW.[...]

De novo DUOX2 expression in neutrophil subsets shapes the pathogenesis of intestinal disease

Singh AK, Ainciburu M, Wynne K, Bhat SA, Blanco A, Tzani I, Akiba Y, Lalor SJ, Kaunitz J, Bourke B, Kelly VP, Doherty GA, Zerbe[...]

Vitamin C reduces gastric pH in pharmacologically induced hypochlorhydria: a potential approach for mitigating pH-dependent drug-drug interactions of weak-base drugs

Fadda HM, Shin A, Waseem MR, Camilleri M. Vitamin C reduces gastric pH in pharmacologically induced hypochlorhydria: a potential approach for mitigating pH-dependent drug-drug interactions[...]